Executive Team

Amy Tseng

Amy Tseng—President & Chief Executive Officer

Amy Tseng is TissueTech’s President and Chief Executive Officer and a member of the company’s Board of Directors. Amy co-founded Bio-Tissue in 1997 and TissueTech in 2001 with the vision of commercializing cryopreserved amniotic membrane as a platform technology for the treatment of ocular surface diseases. Since its inception, Amy has presided over this mission, building Bio-Tissue into the industry leader in this sector and spearheading the founding of Amniox Medical to expand the Company’s technology into other healthcare sectors. She has guided the company through impressive levels of annual growth. Prior to founding Bio-Tissue, Amy spent 10 years with the big five accounting firms, Ernst & Young and Price Waterhouse. Amy holds a Master of Business Administration from the University of Southern California.

Dr Scheffer Tseng

Scheffer C.G. Tseng, MD, PhD—Chief Technology Officer

Dr. Scheffer C. G. Tseng co-founded TissueTech and Bio-Tissue and is currently Chief Technology Officer for TissueTech and Chairman of the company’s Board of Directors. Dr. Tseng is a world-renowned surgeon in ocular surface reconstruction and a widely published physician scientist with more than 300 peer-reviewed clinical and scientific papers. He pioneered limbal stem cell transplantation and developed and commercialized the CryoTek process to preserve the natural therapeutic properties of amniotic membrane. His research focus for the past 30 years has been to identify the active biological components of human placental tissues, to develop alternative products to deliver their therapeutic properties, and to expand their clinical applications. Dr. Tseng holds a medical degree from National Taiwan University and a Doctorate in Experimental Pathology from the University of California. He completed his residency in ophthalmology at the Wilmer Eye Institute at Johns Hopkins, and his fellowship in cornea and external diseases at Massachusetts Eye and Ear Infirmary. Prior to co-founding TissueTech, Dr. Tseng was a Chair Professor at Bascom Palmer Eye Institute, University of Miami Miller School of Medicine.

Devin Buckley

Devin Buckley—Corporate Legal Counsel and Chief Compliance Officer, TissueTech

Devin Buckley joined TissueTech in 2013 with more than 12 years of experience in the life sciences industry. Prior to this, Devin was the Senior Vice President and General Counsel at Stiefel Laboratories, Inc., where he helped build what became the world’s largest dermatology company. Devin previously held positions with United Technologies, United Technologies/Pratt & Whitney, Day, Berry & Howard and Our Kids of Miami-Dade. Devin holds a Bachelor’s Degree from Yale University and a Juris Doctor from Georgetown University.

Mike Cornelius

Michael Cornelius—Chief Financial Officer

Michael Cornelius joined TissueTech as Chief Financial Officer in 2014 with more than 25 years of experience in public accounting and public and private corporations.  Mr. Cornelius was previously with Stiefel Laboratories, serving as its Chief Financial Officer.  Stiefel Laboratories was the largest privately-held dermatology company in the world, before it was acquired by GlaxoSmithKline in 2009. Mike began his career with the international accounting and consulting firm, Grant Thornton, where he specialized in US and International tax planning and also held senior level finance positions with IVAX Corporation and Sunglass Hut International. Mike holds a Bachelor of Science in Business Administration from Indiana University of Pennsylvania and is a Certified Public Accountant.

Thomas Williamson — Chief Commercial Officer

Tom Williamson is a top producing commercial executive with both large company and start-up experience. Under Tom’s leadership, the Stryker Interventional Spine sales team became a revenue growth leader and established a strong foothold in the competitive vertebral compression fracture market. He then joined Entellus Medical where his last role was VP, Commercial Operations. He helped Entellus grow to over $100M in sales and was integral in their acquisition of Spirox and the final exit of Entellus to Stryker for $662M. Tom holds a Bachelor of Science degree in Chemical Engineering from Louisiana State University and has completed extensive leadership training at Harvard University.